
News|Articles|December 1, 2012
Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha
Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
When It Comes to Interleukins and Atopic Dermatitis,13 Is a Lucky Number |Fall Clinical Derm 2025
2
Mona Shahriari, M.D., Discusses Advances in Prurigo Nodularis | Fall Clinical Derm 2025
3
MHE Week in Review – AAO 2025 Highlights
4
New Therapies Targeting OX40 Pathway Offer Hope for Atopic Dermatitis | Fall Clinical Derm 2025
5

















































